MindFirst Mental Health Early-Intervention Platform Earns EMA Approval: Predicting Depressive Episodes 6 Weeks Early
MindBridge's MindFirst platform uses digital phenotyping — analyzing smartphone usage patterns — to predict depressive episodes up to six weeks in advance. In a 10,000-person prospective trial it achieved 83% accuracy and has been approved by the EMA as a digital therapeutic.
Knowing About Depression Six Weeks Before It Hits — MindFirst's Digital Phenotyping Approach
Depression affects more than 300 million people worldwide, yet most patients seek treatment only after an episode has already taken hold — by which time the brain's neurochemical imbalance is well advanced. If warnings could arrive weeks before symptoms worsen, patients could take preventive action.
MindBridge's MindFirst platform aims to make that a reality. Approved by the EMA on April 30, the digital therapeutic detects early signs of depression by analyzing a user's "digital phenotyping" — behavioral patterns in smartphone usage.
The metrics MindFirst monitors include changes in phone usage duration (depression often triggers social withdrawal that alters screen habits), shifts in typing speed and accuracy (an early signal of cognitive decline), changes in social app activity, sleep patterns inferred from phone sensors, and changes in movement range derived from GPS data.
"Depression doesn't strike suddenly — it's a gradual escalation," explained MindBridge's Chief Science Officer Dr. Lisa Chen. "Digital phenotyping can capture the subtle shifts in that process that the human eye would miss."
In a prospective trial involving 10,000 participants, MindFirst issued warnings an average of 6.2 weeks before clinical diagnosis, with 83% accuracy. Among those who received alerts, 65% proactively sought counseling or adjusted their lifestyles, and 40% ultimately never developed clinical depression.
MindFirst operates entirely on a voluntary opt-in basis — users must download the app and authorize data collection. All analysis is performed on-device; behavioral data never leaves the phone.
The EMA classifies MindFirst as a Class IIa digital medical device. MindBridge plans to partner with the UK's NHS to integrate MindFirst into routine mental health screening by 2031.
The personal subscription is 9.99 euros per month; the enterprise tier (for employee mental health support) costs 2 euros per employee per month.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.